White House lays out sprawl­ing new plan to shore up phar­ma and API man­u­fac­tur­ing

As the US in­creas­ing­ly re­lies on for­eign drug and ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) man­u­fac­tur­ing, par­tic­u­lar­ly from Chi­na and In­dia, the Biden-Har­ris ad­min­is­tra­tion ear­ly Tues­day morn­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER